Paper · 41226014
Advancing Prostate Cancer Assessment: A Biparametric MRI (T2WI and DWI/ADC)-Based Radiomic Approach to Predict Tumor-Stroma Ratio.
Ma J and 10 others. Diagnostics (Basel), 2025. Cited by 2 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Advancing Prostate Cancer Assessment: A Biparametric MRI (T2WI and DWI/ADC)-Based Radiomic Approach to Predict Tumor-Stroma Ratio. Papers, record 41226014. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41226014
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Advancing Prostate Cancer Assessment: A Biparametric MRI (T2WI and DWI/ADC)-Based Radiomic Approach to Predict Tumor-Stroma Ratio.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 2024ZDXM004 | Chongqing medical scientific research project (Joint project of Chongqing Health Commission and Science and Technology Bureau) | PubMed |
Source PubMed
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References52
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32,719,249 | Clinicopathological correlation of tumor-stroma ratio and inflammatory cell infiltrate with tumor grade and lymph node metastasis in squamous cell carcinoma of buccal mucosa and tongue in 41 cases with review of literature. | J Cancer Res Ther | 2020 | https://conductscience.org/library/papers/32719249 | PubMed |
| 2 | 35,475,132 | Transition zone prostate cancer is associated with better clinical outcomes than peripheral zone cancer. | BJUI Compass | 2021 | https://conductscience.org/library/papers/35475132 | PubMed |
| 3 | 14,581,350 | Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. | Clin Cancer Res | 2003 | https://conductscience.org/library/papers/14581350 | PubMed |
| 4 | 39,665,990 | Prediction of mucinous adenocarcinoma in colorectal cancer with mucinous components detected in preoperative biopsy diagnosis. | Abdom Radiol (NY) | 2025 | https://conductscience.org/library/papers/39665990 | PubMed |
| 5 | 30,958,743 | Radiomics Features Measured with Multiparametric Magnetic Resonance Imaging Predict Prostate Cancer Aggressiveness. | J Urol | 2019 | https://conductscience.org/library/papers/30958743 | PubMed |
| 6 | 34,820,324 | CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma. | Front Oncol | 2021 | https://conductscience.org/library/papers/34820324 | PubMed |
| 7 | 31,586,850 | Intravoxel incoherent motion diffusion-weighted MRI in patients with breast cancer: Correlation with tumor stroma characteristics. | Eur J Radiol | 2019 | https://conductscience.org/library/papers/31586850 | PubMed |
| 8 | 17,726,261 | The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. | Cell Oncol | 2007 | https://conductscience.org/library/papers/17726261 | PubMed |
| 9 | 34,990,929 | Interpretation of radiomics features-A pictorial review. | Comput Methods Programs Biomed | 2022 | https://conductscience.org/library/papers/34990929 | PubMed |
| 10 | 39,297,055 | Machine Learning-Based Predictive Model for Mortality in Female Breast Cancer Patients Considering Lifestyle Factors. | Cancer Manag Res | 2024 | https://conductscience.org/library/papers/39297055 | PubMed |
1 to 10 of 52
See all 52 referencesCited by2
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,086,354 | Analysis of risk factors for MRI-invisible prostate cancer-the significance of AGGF1 immunohistochemical detection and PSAD. | Can J Urol | 2026 | https://conductscience.org/library/papers/42086354 | PubMed |
| 41,899,600 | Biparametric Versus Multiparametric MRI for VI-RADS Assessment: Reproducibility Relative to Routine mpMRI Reporting and Impact of Radiologist Experience in a Single-Center Study. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/41899600 | PubMed |
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41226014
GET https://conductscience.org/api/papers/v1/41226014/references?page=2